In order to ensure 2023 billing, testing must be activated before the end of the year, or within 30 days of proband sample collection (if sample was collected in 2023). For Exome, Genome, or Xpanded testing, if you do not expect parental samples to be received in time for testing to be activated with 2023 billing, please contact us at email@example.com to determine how to proceed.
That’s the future we’re building at GeneDx.
Comprehensive genomic insights. Precision medicine. Improved outcomes.
November 20, 2023
GeneDx today announced that, effective as of November 17, 2023, the compensation committee of GeneDx’s board of directors granted newly hired employees 10,000 restricted stock units (“RSUs”) as inducements material to each employee entering into employment with GeneDx.
October 30, 2023
GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today reported its financial results for the third quarter of 2023.
October 9, 2023
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financial results for the third quarter of 2023 after the market closes on Monday, October 30, 2023.